Geroscience and longevity: science or marketing?

The article analyzes the evolution of preventive medicine toward geroscience, whose goal is not merely to extend life (lifespan), but to improve the period of functionality (healthspan) through the concept of compression of morbidity. The author discusses the Hallmarks of Aging model as the biological framework of aging, while simultaneously warning against the gap between molecular discoveries and their clinical efficacy in humans. The text critically addresses the commercialization of the longevity movement and popular interventions (e.g., rapamycin, metformin), pointing to the risk of treating scientific hypotheses as ready-made therapeutic standards. Overall, it is a reflection on the tension between rigorous science and marketing in the field of modern life-extension medicine.